7-methyl-6,7-dihydro-5H-pyrrol[1,2-a]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-methyl-6,7-dihydro-5H-pyrrol[1,2-a]imidazole
• 英文别名: 7-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: UYFVSZXUJZCCMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-methylpyrrolidine-2-thione 在 对甲苯磺酸 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 36.0h， 生成 7-methyl-6,7-dihydro-5H-pyrrol[1,2-a]imidazole
  参考文献：
  名称：

  [EN] NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRIDINE ET DE PYRAZOLOPYRIDINE SULFONAMIDE

  摘要：

  The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3and W are as described herein, composition including the compounds and methods of using the compounds.

  公开号：

  WO2024017857A1

文献信息

• [EN] NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND &bgr;-LACTAMASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS ET INHIBITEURS DE &Bgr;-LACTAMASE
  申请人：NAEJA PHARMACEUTICAL INC

  公开号：WO2014091268A1

  公开（公告）日：2014-06-19

  A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式（I）的化合物，其中：M为氢或药用可接受的盐形成阳离子；Y为OR1或NR2R3，R1、R2、R3和M如本文所定义。此外，治疗细菌感染的方法，制药组合物，分子复合物和制备化合物的方法。
• BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS
  申请人：NAEJA PHARMACEUTICAL INC.

  公开号：US20140221341A1

  公开（公告）日：2014-08-07

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR 1 or NR 2 R 3 , and R 1 , R 2 , R 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  化合物的式子(I)：其中：M是氢或药用可接受的盐形成阳离子；Y是OR1或NR2R3，而R1、R2、R3和M的定义如本文所述。此外，还提供了治疗细菌感染的方法、制药组合物、分子复合物和制备化合物的过程。
• Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
  申请人：FEDORA PHARMACEUTICALS INC.

  公开号：US10030019B2

  公开（公告）日：2018-07-24

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式 (I) 的化合物： 其中 M 是氢或药学上可接受的成盐阳离子； Y 是 OR1 或 NR2R3、 以及 R1、R2、R3 和 M 如本文所定义。此外，还有治疗细菌感染的方法、药物组合物、分子复合物和制备化合物的工艺。
• Ketoreductase polypeptides and polynucleotides
  申请人：Codexis, Inc.

  公开号：US11021729B2

  公开（公告）日：2021-06-01

  The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.

  本发明提供了与天然野生型酮还原酶和亚磷酸酯脱氢酶相比具有更好性质的工程酮还原酶和亚磷酸酯脱氢酶，以及编码工程酮还原酶和亚磷酸酯脱氢酶的多核苷酸、能够表达工程酮还原酶和亚磷酸酯脱氢酶的宿主细胞，以及使用工程酮还原酶和亚磷酸酯脱氢酶合成用于合成核苷抑制剂等抗病毒化合物的手性催化剂的方法。本发明进一步提供了在一锅多酶系统中使用工程酶脱手性醇的方法。
• SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US20180044287A1

  公开（公告）日：2018-02-15

  The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.